Allarity SEC Filings

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. (ALLR), reported transactions dated 09/30/2025. 39,494 restricted stock units vested and were reported as acquired, and 14,613 shares were disposed of at $1.58 per share, leaving 24,881 shares owned directly after the transactions. The filing also shows 223,430 restricted stock units/derivative securities beneficially owned following the reported transactions. The RSUs convert one-for-one to common stock and stem from grants of 118,483 RSUs on 09/30/2024 and 144,441 RSUs on 01/22/2025, each vesting in three equal annual installments beginning on the first anniversary of the respective grant dates.

Allarity Therapeutics, Inc. filed an S-3 shelf registration describing an offering that includes 760,916 shares of Common Stock and 801,584 Pre-Funded Warrants exercisable for Common Stock at an exercise price of $0.0001 per share. The company’s authorized capital structure includes 250,000,000 shares of Common Stock and 500,000 shares of undesignated preferred stock. The prospectus enumerates the distribution methods permitted under the plan, including ordinary brokerage transactions, block trades, principal purchases and exchange distributions. The document lists estimated offering expenses including $20,000 for accounting fees and $50,000 for legal fees. A table of exhibits identifies corporate charter amendments, bylaws, a specimen stock certificate, forms of pre-funded warrant, a securities purchase agreement and a registration rights agreement dated September 22, 2025. The filing is signed by the CEO, CFO and multiple directors with signatures dated September 25, 2025.

Allarity Therapeutics, Inc. filed a Form 8-K reporting a material event dated September 22, 2025. The filing lists two material agreements as exhibits: a Form of Securities Purchase Agreement and a Form of Registration Rights Agreement, each dated September 22, 2025, described as between the company and an investor. The document identifies the company's common stock ticker as ALLR on The Nasdaq Stock Market LLC and is signed by Thomas H. Jensen, Chief Executive Officer. The filing includes an Inline XBRL cover page reference but does not disclose financial terms, investor identity, or the size or economic impact of the transaction.

Allarity Therapeutics, Inc. reported interim results showing constrained operations but sufficient near-term liquidity. The company recorded a net loss of $5.1 million for the six months ended June 30, 2025 and negative operating cash flow of $8.2 million over the same period. Management states that $17.8 million of cash, cash equivalents and restricted cash as of June 30, 2025 is estimated to be sufficient to fund operations for at least the next 12 months under the current plan. The company completed corporate actions including Reverse Stock Splits (retroactively applied) and repurchased 2,455,702 shares for $2,565,511, leaving $2,434,489 available under its repurchase program. A legal/contract liability to Novartis resulted in current liabilities recorded as $3.6 million accounts payable, $1.4 million convertible promissory notes and accrued interest, and $0.4 million accrued liabilities. The company settled a prior SEC investigation by paying a $2.5 million civil penalty which was paid in cash on April 2, 2025.

On 15 Jul 2025 Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Form 8-K under Item 8.01 to disclose the execution of a new commercial agreement with an undisclosed EU-based biotechnology company. The filing states only that the agreement was announced via a press release furnished as Exhibit 99.1, which is incorporated by reference.

No financial terms, partner identity, milestones, or projected revenue were provided in the 8-K, and the company did not report any changes to financial statements, guidance, or capital structure. Other 8-K items were not triggered. Investors must review Exhibit 99.1 for substantive economic details before assessing materiality.